Common Variants in ACYP2 Influence Susceptibility to Cisplatin-induced Hearing Loss

Overview

Journal Nat Genet

Specialty Genetics

Date 2015 Feb 10

PMID 25665007

Citations 55

Authors

Heng Xu

Giles W Robinson

Jie Huang

Joshua Yew-Suang Lim

Hui Zhang

Johnnie K Bass

Alberto Broniscer

Murali Chintagumpala

Ute Bartels

Sri Gururangan

Tim Hassall

Michael Fisher

Richard Cohn

Tetsuji Yamashita

Tal Teitz

Jian Zuo

Arzu Onar-Thomas

Amar Gajjar

Clinton F Stewart

Jun J Yang

Affiliations

Soon will be listed here.

Abstract

Taking a genome-wide association study approach, we identified inherited genetic variations in ACYP2 associated with cisplatin-related ototoxicity (rs1872328: P = 3.9 × 10(-8), hazard ratio = 4.5) in 238 children with newly diagnosed brain tumors, with independent replication in 68 similarly treated children. The ACYP2 risk variant strongly predisposed these patients to precipitous hearing loss and was related to ototoxicity severity. These results point to new biology underlying the ototoxic effects of platinum agents.

Citing Articles

Cisplatin-Induced Hearing Loss, Oxidative Stress, and Antioxidants as a Therapeutic Strategy-A State-of-the-Art Review.

Rose O, Croonenberg T, Clemens S, Hinteregger T, Eppacher S, Huber-Cantonati P Antioxidants (Basel). 2025; 13(12.

PMID: 39765905 PMC: 11673797. DOI: 10.3390/antiox13121578.

Leveraging large-scale datasets and single cell omics data to develop a polygenic score for cisplatin-induced ototoxicity.

Miao D, Wilke M, Pham J, Ladha F, Singh M, Arsenio J Hum Genomics. 2024; 18(1):112.

PMID: 39380081 PMC: 11463131. DOI: 10.1186/s40246-024-00679-5.

The role of genetic variants in the prediction of hearing loss due to cisplatin chemoradiotherapy.

Duinkerken C, Chiodo S, Hueniken K, Hauptmann M, Jozwiak K, Cheng D Cancer Med. 2024; 13(16):e7465.

PMID: 39159054 PMC: 11332395. DOI: 10.1002/cam4.7465.

ERK1/2 Inhibition via the Oral Administration of Tizaterkib Alleviates Noise-Induced Hearing Loss While Tempering down the Immune Response.

Lutze R, Ingersoll M, Thotam A, Joseph A, Fernandes J, Teitz T Int J Mol Sci. 2024; 25(12).

PMID: 38928015 PMC: 11204379. DOI: 10.3390/ijms25126305.

KSR1 Knockout Mouse Model Demonstrates MAPK Pathway's Key Role in Cisplatin- and Noise-induced Hearing Loss.

Ingersoll M, Lutze R, Kelmann R, Kresock D, Marsh J, Quevedo R J Neurosci. 2024; 44(18).

PMID: 38548338 PMC: 11063821. DOI: 10.1523/JNEUROSCI.2174-23.2024.

References

Potter D . A permutation test for inference in logistic regression with small- and moderate-sized data sets. Stat Med. 2004; 24(5):693-708. DOI: 10.1002/sim.1931. View

Li Y, Womer R, Silber J . Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer. 2004; 40(16):2445-51. DOI: 10.1016/j.ejca.2003.08.009. View

Kushner B, Budnick A, Kramer K, Modak S, Cheung N . Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer. 2006; 107(2):417-22. DOI: 10.1002/cncr.22004. View

Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun L, Merchant T . Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006; 7(10):813-20. DOI: 10.1016/S1470-2045(06)70867-1. View

Oldenburg J, Kraggerud S, Cvancarova M, Lothe R, Fossa S . Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol. 2007; 25(6):708-14. DOI: 10.1200/JCO.2006.08.9599. View

Patterson N, Price A, Reich D . Population structure and eigenanalysis. PLoS Genet. 2006; 2(12):e190. PMC: 1713260. DOI: 10.1371/journal.pgen.0020190. View

Gurney J, Bass J, Onar-Thomas A, Huang J, Chintagumpala M, Bouffet E . Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. Neuro Oncol. 2014; 16(6):848-55. PMC: 4022215. DOI: 10.1093/neuonc/not241. View

Travis L, Fossa S, Sesso H, Frisina R, Herrmann D, Beard C . Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst. 2014; 106(5). PMC: 4568989. DOI: 10.1093/jnci/dju044. View

Lanvers-Kaminsky C, Malath I, Deuster D, Ciarimboli G, Boos J, Am Zehnhoff-Dinnesen A . Evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity. Clin Pharmacol Ther. 2014; 96(2):156-7. DOI: 10.1038/clpt.2014.67. View

10.

Liu H, Pecka J, Zhang Q, Soukup G, Beisel K, He D . Characterization of transcriptomes of cochlear inner and outer hair cells. J Neurosci. 2014; 34(33):11085-95. PMC: 4131018. DOI: 10.1523/JNEUROSCI.1690-14.2014. View

11.

Fuchs P . A 'calcium capacitor' shapes cholinergic inhibition of cochlear hair cells. J Physiol. 2014; 592(16):3393-401. PMC: 4229337. DOI: 10.1113/jphysiol.2013.267914. View

12.

Huang R, Duan S, Shukla S, Kistner E, Clark T, Chen T . Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet. 2007; 81(3):427-37. PMC: 1950832. DOI: 10.1086/519850. View

13.

Dean J, Hayashi S, Albert C, King A, Karzon R, Hayashi R . Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens. J Pediatr Hematol Oncol. 2008; 30(2):130-4. DOI: 10.1097/MPH.0b013e31815d1d83. View

14.

Fouladi M, Chintagumpala M, Ashley D, Kellie S, Gururangan S, Hassall T . Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol. 2008; 26(22):3749-55. PMC: 2504739. DOI: 10.1200/JCO.2007.14.3974. View

15.

Choy E, Yelensky R, Bonakdar S, Plenge R, Saxena R, De Jager P . Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell lines. PLoS Genet. 2008; 4(11):e1000287. PMC: 2583954. DOI: 10.1371/journal.pgen.1000287. View

16.

Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B . Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009; 361(17):1662-70. DOI: 10.1056/NEJMoa0810613. View

17.

Ross C, Katzov-Eckert H, Dube M, Brooks B, Rassekh S, Barhdadi A . Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet. 2009; 41(12):1345-9. DOI: 10.1038/ng.478. View

18.

Chang K, Chinosornvatana N . Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol. 2010; 28(10):1788-95. DOI: 10.1200/JCO.2009.24.4228. View

19.

Mukherjea D, Rybak L . Pharmacogenomics of cisplatin-induced ototoxicity. Pharmacogenomics. 2011; 12(7):1039-50. PMC: 3217465. DOI: 10.2217/pgs.11.48. View

20.

Qaddoumi I, Bass J, Wu J, Billups C, Wozniak A, Merchant T . Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol. 2012; 30(10):1034-41. PMC: 3341147. DOI: 10.1200/JCO.2011.36.9744. View